>>12008521(lb)

I posted this late last bread so posting again.

PATHOGENIC PRIMING AND THE COVID VACCINE

An Anon previously posited that the vaccine may by the actual bioweapon. The article below I think adds some credibility to this line of thinking.

This is an important read of what the covid vaccine may really be doing…priming the body's immune system to attack the body itself (i.e.: autoimmunity) if/when a person is infected with the virus AFTER they are vaccinated. According to the article, the vaccine does not protect against infection.

https://www.greenmedinfo.com/blog/pfizer-covid-vaccine-trial-shows-alarming-evidence-pathogenic-priming-older-adult?utm_campaign=DAILY%20Newsletter%3A%20Warp%20Speed%20Live%20%2B%20December%2012%20%28VQM5cr%29&utm_medium=email&utm_source=Daily%20Newsletter&_ke=eyJrbF9lbWFpbCI6ICJ2a293YWxAdGVsdXMubmV0IiwgImtsX2NvbXBhbnlfaWQiOiAiSzJ2WEF5In0%3D

>>12008633

There was a post a while back written supposedly by an insider in Canada's federal Liberal Party. In his post he mentioned the release of a second, more lethal, viral strain (COVID21).

Could the vaccine be priming the immune system for a severe autoimmune flare-up in response to infection with this new strain–a super cytokine storm?

>>12008673

Apologies Anon. They do not know if the vaccine can prevent transmission of the virus as the studies are not looking at that.

"What about Hotez’s second criterion, interrupting virus transmission, which some experts have argued17 should be the most important test in phase III studies?

“Our trial will not demonstrate prevention of transmission,” Zaks said, “because in order to do that you have to swab people twice a week for very long periods, and that becomes operationally untenable.”

He repeatedly emphasised these “operational realities” of running a vaccine trial. “Every trial design, especially phase III, is always a balancing act between different needs,” he said. “If you wanted to have an answer on an endpoint that happens at a frequency of one 10th or one fifth the frequency of the primary endpoint, you would need a trial that is either 5 or 10 times larger or you’d need a trial that is 5 or 10 times longer to collect those events. Neither of these, I think, are acceptable in the current public need for knowing expeditiously that a vaccine works.”

Zaks added, “A 30 000 [participant] trial is already a fairly large trial. If you’re asking for a 300 000 trial then you need to talk to the people who are paying for it, because now you’re talking about not a $500m to $1bn trial, you’re talking about something 10 times the size. And I think the public purse and operational capabilities and capacities we have are rightly spent not betting the farm on one vaccine but, as Operation Warp Speed [the US government’s covid-19 vaccine plan] is trying to do, making sure that we’re funding several vaccines in parallel.” "

https://www.bmj.com/content/371/bmj.m4037